Next Article in Journal / Special Issue
Radiotherapy Advances in Pediatric Neuro-Oncology
Previous Article in Journal
Evaluation of HLA-G Expression in Multipotent Mesenchymal Stromal Cells Derived from Vitrified Wharton’s Jelly Tissue
Previous Article in Special Issue
Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessCommunication
Bioengineering 2018, 5(4), 96; https://doi.org/10.3390/bioengineering5040096

Polo-Like Kinase 4 (PLK4) Is Overexpressed in Central Nervous System Neuroblastoma (CNS-NB)

1
Division of Pediatric Neurosurgery, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL 60611, USA
2
Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
3
Cancer Biology and Epigenomics Program, Stanley Manne Children’s Research Institute, Chicago, IL 60614, USA
4
Department of Pathology, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL 60611, USA
5
Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
6
Department of Biology, Elmhurst College, Elmhurst, IL 60126, USA
*
Author to whom correspondence should be addressed.
Authors with equal contribution.
Received: 28 August 2018 / Revised: 19 October 2018 / Accepted: 1 November 2018 / Published: 4 November 2018
(This article belongs to the Special Issue Update in Pediatric Neuro-Oncology)
Full-Text   |   PDF [1359 KB, uploaded 4 November 2018]   |  

Abstract

Neuroblastoma (NB) is the most common extracranial solid tumor in pediatrics, with rare occurrences of primary and metastatic tumors in the central nervous system (CNS). We previously reported the overexpression of the polo-like kinase 4 (PLK4) in embryonal brain tumors. PLK4 has also been found to be overexpressed in a variety of peripheral adult tumors and recently in peripheral NB. Here, we investigated PLK4 expression in NBs of the CNS (CNS-NB) and validated our findings by performing a multi-platform transcriptomic meta-analysis using publicly available data. We evaluated the PLK4 expression by quantitative real-time PCR (qRT-PCR) on the CNS-NB samples and compared the relative expression levels among other embryonal and non-embryonal brain tumors. The relative PLK4 expression levels of the NB samples were found to be significantly higher than the non-embryonal brain tumors (p-value < 0.0001 in both our samples and in public databases). Here, we expand upon our previous work that detected PLK4 overexpression in pediatric embryonal tumors to include CNS-NB. As we previously reported, inhibiting PLK4 in embryonal tumors led to decreased tumor cell proliferation, survival, invasion and migration in vitro and tumor growth in vivo, and therefore PLK4 may be a potential new therapeutic approach to CNS-NB. View Full-Text
Keywords: embryonal brain tumor; pediatric; CNS-PNET; low grade glioma; rhabdoid; ATRT; medulloblastoma; kinase inhibitor embryonal brain tumor; pediatric; CNS-PNET; low grade glioma; rhabdoid; ATRT; medulloblastoma; kinase inhibitor
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed
Printed Edition Available!
A printed edition of this Special Issue is available here.

Share & Cite This Article

MDPI and ACS Style

Bailey, A.W.; Suri, A.; Chou, P.M.; Pundy, T.; Gadd, S.; Raimondi, S.L.; Tomita, T.; Sredni, S.T. Polo-Like Kinase 4 (PLK4) Is Overexpressed in Central Nervous System Neuroblastoma (CNS-NB). Bioengineering 2018, 5, 96.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Bioengineering EISSN 2306-5354 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top